logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics opts to split phase III grass allergy study over two pollen seasons

It has done so after consulting experts and taking on board feedback from its phase III Birch MATA MPL trial

Allergy Therapeutics PLC -
This will allow Allergy to carry out an interim analysis of the data at the halfway stage

Allergy Therapeutics PLC (LON:AGY) said it is taking a “stepwise approach” to its upcoming phase III trial of its Grass MATA MPL vaccine for hay fever.

Instead of embarking on one large study it will split the process in two – covering the 2020/2021 and 2021/2022 pollen seasons.

This will allow Allergy to carry out an interim analysis of the data at the halfway stage.

Allergy has opted to split the clinical assessment this way after consulting experts and taking on board feedback from its phase III Birch MATA MPL study.

"The planning for our Grass MATA MPL phase III study is now completed and we look forward to starting this important trial," Allergy chief executive Manuel Llobet said in a statement.

Separately, Allergy said results from the group's successful phase II trial of the grass pollen vaccine, which assessed the dose to be taken into phase III, were recently published in the World Allergy Organisation Journal.

As the name suggests, Allergy Therapeutics, which is headquartered in Worthing, West Sussex and employs around 500 people, develops inoculations against common allergies.

It has five products registered, as well as another five that are available on a named patient basis – this means they can only be prescribed by a doctor.

It has a strong presence in Europe, with established operations in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the United Kingdom, while in other markets, it often makes its products available through distribution partners.

Quick facts: Allergy Therapeutics PLC

Price: 14.74 GBX

AIM:AGY
Market: AIM
Market Cap: £93.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: Coronavirus vaccine update sparks FTSE 100 rally

Headlines from the Proactive UK newsroom. The FTSE 100 rallied 60 points to 6,240 on COVID-19 vaccine hopes. US group Moderna’s early stage trial of a coronavirus vaccine proved safe and sparked some immune response. UK inflation picked up to 0.6% led by demand for online computer games...

3 weeks, 5 days ago

2 min read